Trump signs executive order to accelerate PTSD therapy research: US psychedelic drug sector sees a "structural turning point", with stocks soaring across the board before the market opens

After President Trump signed an executive order aimed at accelerating research and expanding access to overseas substances used to treat Post Traumatic Stress Disorder (PTSD), psychedelic-related stocks rose in pre-market trading. Among the volatile stocks, Compass Pathways (CMPS.US) rose by 25%, Atai Beckley (ATAI.US) by 22%, Definium Therapeutics (DFTX.US) by 20%, GH Research (GHRS.US) and Cybin (HELP.US) each surged by 17%. Jay Olson, an analyst at Oppenheimer, stated that Trump's executive order "represents a structural inflection point for the psychedelic industry in the United States by promoting research, simplifying regulatory timelines, and expanding patient access channels, reinforcing our positive outlook." Olson continues to favor Atai Beckley, Compass Pathways, and Definium Therapeutics, stating that they have a "differentiation advantage." Jefferies Financial Group Inc. analyst Andrew Chai noted that with multiple government agencies, including the Trump administration, the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and the Department of Veterans Affairs (VA) reaching consensus, investor focus is likely to significantly increase before potential approvals and implementations between 2027 and 2030. The report added that the commercialization process may now accelerate. Meanwhile, Royal Bank of Canada (RBC) analyst Brian Abrahams believes that the executive order "accelerates the development of psychedelic drugs as the next wave of key therapies for mental health." The report highlighted this positive development in the field, benefiting psychedelic drug companies covered by RBC: Definium Therapeutics, Compass Pathways, and GH Research.